![Francisco Salva](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Francisco Salva
Directeur Général chez
AZITRA, INC.
Fortune : 412 $ au 31/05/2026
Profil
Francisco D.
Salva was the founder of Acerta Pharma BV, founded in 2012, where the title held was Vice President-Operations from 2013 to 2016.
Mr. Salva currently works at Azitra, Inc. as President, Chief Executive Officer & Director since 2021.
Former jobs include President, Chief Executive Officer & Director at Complexa, Inc. from 2018 to 2020, Senior Director-Corporate Finance at Pharmacyclics LLC, Independent Director at Vincerx Pharma, Inc. from 2020 to 2025, and Operating Partner at Accelerator Services Corp.
Education includes undergraduate studies at Brown University and graduate studies at the London School of Economics & Political Science.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
AZITRA INC 0,01% | 24/04/2026 | 1 771 ( 0,01% ) | 407 $ | 31/05/2026 |
VINCERX PHARMA INC 0,01% | 21/03/2025 | 333 ( 0,01% ) | 4 $ | 31/05/2026 |
Postes actifs de Francisco Salva
| Sociétés | Poste | Début |
|---|---|---|
| AZITRA, INC. | Directeur Général | 04/05/2021 |
Anciens postes connus de Francisco Salva
| Sociétés | Poste | Fin |
|---|---|---|
| VINCERX PHARMA, INC. | Directeur/Membre du Conseil | 30/06/2025 |
Complexa, Inc.
 Complexa, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company which focuses on discovering and developing therapies for the treatment inflammatory and metabolic diseases | Directeur Général | 01/08/2020 |
Acerta Pharma BV
 Acerta Pharma BV Pharmaceuticals: GenericHealth Technology Develops drugs for oncology and autoimmune diseases | Fondateur | 01/11/2016 |
Accelerator Services Corp
 Accelerator Services Corp Investment ManagersFinance Accelerator Services invests in companies located in the United States. The firm focuses on the healthcare sector. It provides financing for early stage capital requirements. | Corporate Officer/Principal | - |
| PHARMACYCLICS, INC. | Directeur Financier/CFO | - |
Formation de Francisco Salva
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
10
Relations au 1er degré
8
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 8 |
|---|---|
Pharmacyclics LLC
 Pharmacyclics LLC Pharmaceuticals: MajorHealth Technology Manufactures drugs intended to treat cancer and atherosclerosis | Health Technology |
Brown University
 Brown University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
London School of Economics & Political Science
 London School of Economics & Political Science Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Accelerator Services Corp
Accelerator Services Corp Investment ManagersFinance Accelerator Services invests in companies located in the United States. The firm focuses on the healthcare sector. It provides financing for early stage capital requirements. | Finance |
Complexa, Inc.
Complexa, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company which focuses on discovering and developing therapies for the treatment inflammatory and metabolic diseases | Health Technology |
Acerta Pharma BV
Acerta Pharma BV Pharmaceuticals: GenericHealth Technology Develops drugs for oncology and autoimmune diseases | Health Technology |
Azitra, Inc.
 Azitra, Inc. Pharmaceuticals: MajorHealth Technology Operates as an clinical biopharmaceutical company that develops and commercializes therapies for precision dermatology | Health Technology |
Vincerx Pharma, Inc.
 Vincerx Pharma, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biopharmaceutical company that develops therapies to address cancer | Health Technology |
